Oppenheimer starts ‘regenerative medicine story’ at Outperform. Oppenheimer analyst Steven Lichtman initiated coverage of Organogenesis with an Outperform rating and $11 price target. The company has a “diverse product set at different levels of complexity and price points that address a wide spectrum of wounds and musculoskeletal injuries,” Lichtman tells investors in a research note. The analyst sees Organogenesis’ markets as growing more than high-single digits and not highly penetrated. He calls the company as a “well-positioned regenerative medicine story.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.